Ascendis Pharma A (ASND) Amortization (2012 - 2026)

Ascendis Pharma A has disclosed Amortization across 15 years of filings, most recently posting $1.3 billion for Q1 2026.

• Amortization for Q1 2026 came in at $1.3 billion, up 36.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 36.09% YoY), and the FY2025 annual result was $1.3 billion, down 44.44% from the prior year.
• Amortization came in at $1.3 billion for Q1 2026 at Ascendis Pharma A, up from $1.3 billion in the prior quarter.
• In the past five years, Amortization ranged from a high of $2.3 billion in Q4 2024 to a low of $737.9 million in Q2 2023.
• The 5-year median for Amortization is $1.1 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Amortization jumped 14306.07% in 2022 and plunged 44.44% in 2025, its largest moves.
• Ascendis Pharma A's Amortization stood at $942.2 million in 2022, then fell by 15.89% to $792.4 million in 2023, then soared by 193.2% to $2.3 billion in 2024, then plunged by 44.44% to $1.3 billion in 2025, then increased by 2.19% to $1.3 billion in 2026.
• The last three Amortization figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.